Valuation: Tsubota Laboratory Incorporated

Market Cap 6.4B 40.8M 35.46M 33.11M 30.39M 57.31M 3.89B 58.31M 390M 153M 1.94B 153M 150M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 5.5B 35.06M 30.47M 28.44M 26.11M 49.24M 3.34B 50.09M 335M 131M 1.67B 132M 129M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
06-16 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
05-31 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
05-31 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
05-15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
02-13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
02-13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
25-05-11 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
25-02-17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
24-11-20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
22-12-18 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
22-09-19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
22-06-23 Tsubota Laboratory Incorporated has completed an IPO in the amount of Ñ1.8048 billion. CI
Manager TitleAgeSince
President 71 2019-01-31
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 2024-12-31
Director TitleAgeSince
Director/Board Member 71 2019-01-31
Director/Board Member 70 2020-05-31
Director/Board Member 55 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 39.98M
-0.36%+0.14%-2.06%+14.33% 48.53B
-2.71%-2.99%+398.09%+472.12% 39.87B
-0.71%+9.45%+27.90%+7.89% 38.68B
-0.71%-3.72%+4.94%+52.45% 35.13B
-2.41%+1.96%+11.68%+38.17% 29.79B
-0.66%-2.73%+35.50%+122.17% 16.11B
-0.19%-3.93% - - 16.08B
-0.62%+1.23%+2.76%+15.05% 13.61B
-3.15%-6.14%-4.82%-36.90% 12.62B
Average -1.15%-0.00%+59.25%+85.66% 27.82B
Weighted average by Cap. -1.24%+1.16%+76.47%+104.59%

Financials

2025 2026
Net sales 1.36B 8.66M 7.52M 7.02M 6.45M 12.16M 825M 12.37M 82.81M 32.43M 411M 32.51M 31.79M 200M 1.28M 1.11M 1.04M 950K 1.79M 122M 1.82M 12.21M 4.78M 60.64M 4.79M 4.69M
Net income 205M 1.31M 1.14M 1.06M 974K 1.84M 125M 1.87M 12.51M 4.9M 62.15M 4.91M 4.8M -761M -4.85M -4.22M -3.94M -3.62M -6.82M -463M -6.94M -46.44M -18.19M -231M -18.23M -17.83M
Net Debt -1.45B -9.24M -8.03M -7.49M -6.88M -12.97M -880M -13.2M -88.36M -34.61M -439M -34.69M -33.92M -901M -5.75M -4.99M -4.66M -4.28M -8.07M -548M -8.21M -54.98M -21.53M -273M -21.59M -21.11M
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-